MLTX Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -2841.85%. MoonLake Immunotherapeutics's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 297.88%. Given that Addex Therapeutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe Addex Therapeutics is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.757, suggesting its more volatile than the S&P 500 by 75.723%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. MoonLake Immunotherapeutics's net income of -$45.6M is lower than Addex Therapeutics's net income of -$1.8M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 13.93x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -106.6%. MoonLake Immunotherapeutics's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.60 which suggests that it could grow by 98.48%. Given that MoonLake Immunotherapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe MoonLake Immunotherapeutics is more attractive than CRISPR Therapeutics AG.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.677%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. MoonLake Immunotherapeutics's net income of -$45.6M is lower than CRISPR Therapeutics AG's net income of -$37.3M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Molecular Partners AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -2408.81%. MoonLake Immunotherapeutics's return on equity of -- beat Molecular Partners AG's return on equity of -37.36%.

MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand Molecular Partners AG has an analysts' consensus of $10.78 which suggests that it could grow by 148.97%. Given that Molecular Partners AG has higher upside potential than MoonLake Immunotherapeutics, analysts believe Molecular Partners AG is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. MoonLake Immunotherapeutics's net income of -$45.6M is lower than Molecular Partners AG's net income of -$12.8M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 21.67x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -- beat NLS Pharmaceutics's return on equity of --.

MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 15089.87%. Given that NLS Pharmaceutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe NLS Pharmaceutics is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$45.6M is higher than NLS Pharmaceutics's net income of --. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.